Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 6,802 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $6.06, for a total value of $41,220.12. Following the sale, the chief financial officer now owns 306,391 shares in the company, valued at $1,856,729.46. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Relay Therapeutics Trading Down 3.2 %
RLAY stock opened at $5.71 on Thursday. The firm's 50-day moving average is $6.93 and its two-hundred day moving average is $7.03. The company has a market capitalization of $764.51 million, a price-to-earnings ratio of -2.27 and a beta of 1.64. Relay Therapeutics, Inc. has a 52 week low of $5.70 and a 52 week high of $12.14.
Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.69) earnings per share for the quarter, topping analysts' consensus estimates of ($0.73) by $0.04. During the same period last year, the company earned ($0.81) earnings per share. On average, equities research analysts predict that Relay Therapeutics, Inc. will post -2.84 earnings per share for the current year.
Wall Street Analysts Forecast Growth
There is a little known company that is changing warfare
From Reticulate | Ad
With geo - political instability around the world investors are flocking to defense contract stocks.
There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.
Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t
A number of brokerages recently commented on RLAY. The Goldman Sachs Group began coverage on Relay Therapeutics in a research note on Tuesday, September 10th. They set a "buy" rating and a $20.00 price objective for the company. Jefferies Financial Group upgraded shares of Relay Therapeutics from a "hold" rating to a "buy" rating and upped their price target for the stock from $10.60 to $16.00 in a research report on Tuesday, September 10th. JPMorgan Chase & Co. cut their price objective on shares of Relay Therapeutics from $23.00 to $21.00 and set an "overweight" rating on the stock in a research report on Tuesday, September 10th. Oppenheimer cut shares of Relay Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Tuesday, September 10th. Finally, Barclays lifted their price target on Relay Therapeutics from $14.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, September 10th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $21.11.
Read Our Latest Research Report on RLAY
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of RLAY. Russell Investments Group Ltd. raised its position in Relay Therapeutics by 57.2% in the first quarter. Russell Investments Group Ltd. now owns 179,972 shares of the company's stock worth $1,494,000 after acquiring an additional 65,484 shares in the last quarter. Logos Global Management LP acquired a new position in shares of Relay Therapeutics in the 2nd quarter worth approximately $8,476,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Relay Therapeutics in the 1st quarter worth approximately $79,000. Los Angeles Capital Management LLC raised its holdings in shares of Relay Therapeutics by 661.7% in the 2nd quarter. Los Angeles Capital Management LLC now owns 106,169 shares of the company's stock worth $692,000 after purchasing an additional 92,230 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Relay Therapeutics by 19.1% during the second quarter. Renaissance Technologies LLC now owns 909,037 shares of the company's stock valued at $5,927,000 after purchasing an additional 145,837 shares during the last quarter. Institutional investors own 96.98% of the company's stock.
Relay Therapeutics Company Profile
(
Get Free Report)
Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
